8-K: Alaunos Therapeutics Secures $500,000 Investment via Convertible Preferred Stock Offering

Alaunos Therapeutics entered into a subscription agreement with Watermill Asset Management, issuing Series A-1 Convertible Preferred Stock for $500,000 in a private offering.

Summary

• Alaunos Therapeutics entered into a Subscription Agreement with Watermill Asset Management on April 11, 2025.
• The agreement involves the issuance and sale of Series A-1 Convertible Preferred Stock at $1,000 per share for an aggregate purchase price of $500,000.
• The offering closed on April 11, 2025.
• The company designated 1,000 shares of Series A-1 Preferred Stock.
• Holders of the Series A-1 Preferred Stock will receive dividends at a rate of 10% per annum, payable in shares of Series A-1 Preferred Stock.
• Holders of Series A-1 Preferred Stock are entitled to vote alongside holders of Common Stock on an as-converted basis on a 1:1 ratio.
• Each share of Series A-1 Preferred Stock is convertible into Common Stock at an initial fixed Conversion Price of $2.76 per share, subject to adjustments.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company successfully raised capital, but the terms of the preferred stock and the restrictions on transferability introduce some risks for investors.

Positives

• Alaunos Therapeutics successfully raised $500,000 in funding.
• The terms of the Series A-1 Preferred Stock include a 10% annual dividend, providing a potential return for the investor.
• The preferred stock's voting rights on an as-converted basis give the investor influence in company decisions.

Negatives

• The conversion price of $2.76 may be viewed as high or low depending on the current market price of the common stock.
• The dividend is payable in shares of Series A-1 Preferred Stock, not cash, which may not be desirable for all investors.

Risks

• The securities were offered and sold in a private placement and have not been registered under the Securities Act of 1933, limiting their transferability.
• The Subscription Agreement includes restrictions on the transfer of the securities.
• The investor bears the risk of potential dilution due to the conversion of preferred stock into common stock.
• The investor is subject to a beneficial ownership limitation of 4.99%.

Future Outlook

The company intends to file a registration statement covering the resale of the Underlying Shares and any other shares of Common Stock held by the Subscribers within 90 calendar days following the Closing.

Industry Context

This type of financing is common for biotech companies seeking capital to fund research and development. Convertible preferred stock allows investors to participate in potential upside while providing downside protection through liquidation preferences and dividend rights.

Comparison to Industry Standards

• Comparable companies in the biotech sector often utilize private placements of convertible preferred stock to raise capital.
• The 10% dividend rate is within the typical range for preferred stock offerings in the biotech industry, but the fact that it is payable in shares of Series A-1 Preferred Stock is unusual.
• The conversion price of $2.76 will need to be compared to the market price of Alaunos Therapeutics' common stock to determine if it is favorable to investors.
• Similar deals include [hypothetical example] XYZ Biotech's $1 million convertible preferred stock offering with a 8% dividend and a conversion price of $5.00.

Stakeholder Impact

• Shareholders may experience dilution if the preferred stock is converted into common stock.
• The capital infusion could enable Alaunos Therapeutics to advance its research and development programs, potentially benefiting patients and employees.
• The company's relationship with Watermill Asset Management could lead to further investment opportunities in the future.

Next Steps

• Alaunos Therapeutics will issue the Series A-1 Convertible Preferred Stock to Watermill Asset Management.
• The company will file a registration statement for the resale of the underlying common stock within 90 days.
• Watermill Asset Management will monitor its investment and may choose to convert its preferred stock into common stock based on market conditions.

Key Dates

Keywords

Series A-1 Convertible Preferred Stock, Subscription Agreement, Private Placement, Watermill Asset Management, Alaunos Therapeutics, Funding, Investment